// App-Quantinova.ai

1501 : Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)

Researchers

Presenter

  • Hagop M. Kantarjian

Principal Investigators

  • Deborah A. Thomas

  • Marina Konopleva

  • Naveen Pemmaraju

  • Marry A Kelly

  • Rebecca Garris

  • Susan O'Brien

  • Stefan Faderl

  • Farhad Ravandi

  • Tapan M. Kadia

  • Jan A. Burger

  • Gautam Borthakur

  • Jorge E. Cortes

  • Naval Daver

  • Elias J. Jabbour

  • Charles Asa Koller

Medical Centers

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Peripheral neuropathy

  • Lymphomas

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Allmercap

  • Methotrexate

  • Asparaginase

  • Vincristine

  • Nelarabine

  • Prednisone

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved